Laura K. Schnackenberg

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

◆ ARA Academy High Impact

ARA Fellow

NCTR primary UAMS University of Arkansas

Also affiliated: University of North Carolina at Chapel Hill (2005); University of Hawaiʻi at Mānoa (2006–2007); United States Department of Health and Human Services (2006); Arkansas Children's Hospital (2009); United States Food and Drug Administration (2005–2026); Kangwon National University (2006–2007); Central Arkansas Veterans Healthcare System (2013); National Cerebral and Cardiovascular Center (2007); Chugai Research Institute For Medical Science, Inc. (Japan) (2007); Obihiro University of Agriculture and Veterinary Medicine (2007); Kumamoto University (2007)

34 h-index 86 pubs 3,567 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group

OverviewAI-generated summary

Laura K. Schnackenberg's research focuses on the application of metabolomics and analytical chemistry techniques to understand toxicology and disease mechanisms. She has investigated the metabolomic evaluation of urine from rats exposed to acetaminophen, employing both Nuclear Magnetic Resonance (NMR) and Ultra-Performance Liquid Chromatography coupled with Mass Spectrometry (UPLC/MS). Schnackenberg has also explored metabolomic approaches for identifying biomarkers of drug-induced hepatotoxicity and nephrotoxicity, including studies on cisplatin-induced nephrotoxicity and acute kidney injury in children following cardiac surgery. Her work also extends to serum metabolomic profiles from patients with acute kidney injury.

Further research interests include the quantification and detection of heterocyclic aromatic amines in cooked foods and grill scrapings using High-Performance Liquid Chromatography (HPLC) with Electrospray Ionization Mass Spectrometry (ESI-MS). Schnackenberg has also studied the regulation of autophagy and apoptosis in vascular smooth muscle cells in response to oxidized low-density lipoprotein (ox-LDL) and the modulatory effects of microRNAs. Her research has been published in peer-reviewed journals, and she is recognized as an ARA Fellow and a highly cited researcher.

Metrics

h-index: 34
Publications: 86
Citations: 3,567

Positions

Division Director 2022–present

National Center for Toxicological Research Division of Systems Biology ORCID
ARA Fellow publications 2005–2026

National Center for Toxicological Research Institutional directory
Supervisory Research Chemist, Branch Chief - Innovation Science & Technology (IST) Branch 2019–2022

National Center for Toxicological Research Division of Systems Biology ORCID
Research Chemist 2005–2019

National Center for Toxicological Research Division of Systems Biology ORCID

Selected Publications

Balancing efficacy and safety: protein kinase inhibitors and drug-induced liver injury (2026)

Elsevier eBooks DOI OpenAlex
Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform (2025)

Toxicology Letters 4 citations DOI OpenAlex
Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids (2025)

Biochemistry and Biophysics Reports 4 citations DOI OpenAlex
Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025)

Biochemical and Biophysical Research Communications 4 citations DOI OpenAlex
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)

Toxicological Sciences 4 citations DOI OpenAlex
Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury (2022)

Current Protocols 34 citations DOI OpenAlex
Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy (2021)

Journal of Chromatography B 17 citations DOI OpenAlex
Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients (2021)

Kidney360 34 citations DOI OpenAlex
MALDI imaging mass spectrometry: an emerging tool in neurology (2021)

Metabolic Brain Disease 40 citations DOI OpenAlex
Metabolomics Test Materials for Quality Control: A Study of a Urine Materials Suite (2019)

Metabolites 22 citations DOI OpenAlex
Stability of the Human Plasma Proteome to Pre-analytical Variability as Assessed by an Aptamer-Based Approach (2019)

Journal of Proteome Research 31 citations DOI OpenAlex
An Integrated Analysis of Metabolites, Peptides, and Inflammation Biomarkers for Assessment of Preanalytical Variability of Human Plasma (2019)

Journal of Proteome Research 27 citations DOI OpenAlex
An Aptamer‐Based Approach to Assess the Human Plasma Proteome for Pre‐Analytical Variability (2018)

The FASEB Journal DOI OpenAlex
Aptamer-Based Proteomics Identifies Mortality-Associated Serum Biomarkers in Dialysis-Dependent AKI Patients (2018)

Kidney International Reports 22 citations DOI OpenAlex
Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans (2017)

Archives of Toxicology 64 citations DOI OpenAlex

View all publications on OpenAlex →

ARA Academy 2021 ARA Fellow

Dr. Schnackenberg's work centers on applying advanced analytical chemistry to toxicology and drug safety. From 2003-2019, she focused on NMR metabolomics to evaluate drug toxicity mechanisms. She subsequently adopted MALDI imaging mass spectrometry techniques. As Branch Chief, she directs projects including drug-induced hepatotoxicity biomarker evaluation, patient-specific cell line responses to tyrosine kinase inhibitors, and novel mass spectrometry tools for bacterial and viral identification.

Policy Impact

Directs FDA research programs advancing drug safety evaluation and mass spectrometry tools for pathogen identification, strengthening Arkansas's federal research presence.